The Central Drugs Standard Control Organisation (CDSCO) approved Chimeric Antigen Receptor or CAR T-cell, named Qartemi by Immuneel Therapeutics, for adult B-cell Non-Hodgkin Lymphoma (B-NHL). This comes nearly a year after NexCAR19, the countrys first homegrown immunotherapy, CAR-T therapy, was approved by CDSCO. Qartemi is a living drug that has been approved for blood cancer patients who suffer from an advanced or relapsed stage of the disease. The drug has been developed by ImmunoACT, a c